



## Biocon Biologics in Turkey: Factsheet

**Biocon Biologics is a leading global biosimilars company committed to addressing patients' needs for cost-effective, high-quality biosimilars.**

### VISION

To be a global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients' lives.

### VALUES

- Innovation & differentiation
- Quality through compliance & best practices
- Integrity and ethical behaviour
- Collaboration, teamwork and mutual respect
- Performance-driven culture

### Company Profile

**Biocon Biologics is present in over 120 countries globally, including more than 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.**

In the Africa-Middle East, Turkey (AFMET) region, Biocon Biologics is making a significant impact on patients' lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 6 commercialized biosimilars.

Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the AFMET region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.

Turkey is among the key focus countries for Biocon Biologics in the AFMET region, where biosimilars adoption is steadily increasing. The company is focused on broadening access to biosimilars for the benefit of patients and improving healthcare outcomes in Turkey. Since 2018, Biocon Biologics has partnered with Abdi Ibrahim, Turkey's leading pharmaceutical company, addressing the needs of thousands of breast cancer patients in the country.

Bengaluru-headquartered Biocon Biologics has a longstanding presence in the biosimilars industry, having invested over \$1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner Viatris has further strengthened Biocon Biologics' commercial presence in Turkey. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Turkey, making a meaningful impact on patients' lives.

## The Biocon Biologics Advantage

- **PATIENT-CENTRICITY:** Dedicated to expanding patient reach and generating significant savings for patients, payers, and healthcare systems.
- **LAB-TO-MARKET EXPERTISE:** Fully integrated from biosimilars development to manufacturing, distribution, and commercialization.
- **LEGACY OF SUCCESS:** Achieved several industry firsts with U.S. approvals for biosimilar Trastuzumab, biosimilar Pegfilgrastim, and interchangeable biosimilar Insulin Glargine.
- **UNIQUE PORTFOLIO:** A comprehensive and differentiated portfolio of biosimilars, including insulins, monoclonal antibodies, and conjugated recombinant proteins.
- **GLOBAL SCALE PRODUCTION:** Operates three large-scale, globally compliant biosimilars manufacturing facilities, ranking among the top 15\* companies worldwide in biomanufacturing capacity.
- **WIDE COMMERCIAL FOOTPRINT:** Commercialized products in 120+ countries through a combination of direct presence, strategic partnerships, and distributors.
- **HIGH QUALITY & COMPLIANCE STANDARDS:** Manufacturing facilities have received 90+ cGMP approvals from over 25 agencies, including the U.S. FDA and EMA.

\*19th Annual Report of BioPlan Associates

## Our Products in Turkey

Brand Name	Molecule
Canhera	Trastuzumab*

\*Commercialized by our partner Abdi Ibrahim in Turkey

## Biocon Biologics in Turkey

### Business Partnership

**Souhail Tebib**  
Head of AFMET-CIS  
souhail.tebib@biocon.com

**Susheel Umesh**  
Chief Commercial Officer,  
Emerging Markets  
Email: susheel.umesh@biocon.com


### Media

**Seema Ahuja**  
Global Head of Corporate Brand & Head  
of Communications – EMs  
Email: seema.ahuja@biocon.com

### Adverse Events

**Email:**  
DrugSafety@biocon.com

## QUICK FACTS



## 4A Model of Enabling Health Equity

- **Affordability:** Rationalizing treatment costs while improving healthcare outcomes.
- **Availability:** Ensuring reliable product supplies across Advanced and Emerging Markets.
- **Accessibility:** Maximizing patient reach through country-specific self and partner-led commercial models.
- **Assurance:** Establishing a trustworthy brand that stands for the highest global quality.

## Global Portfolio

Trastuzumab	Insulin Glargine
Bevacizumab	Insulin Aspart
Pegfilgrastim	Adalimumab
rh-Insulin	Etanercept
Ustekinumab	

Last updated: March, 2025

For more information:  
Biocon Biologics Corporate Factsheet  
Website: <https://www.bioconbiologics.com>



Transforming Healthcare. Transforming Lives.